A joint meeting was held between the executives of Golrang Pharmaceutical Investment Group and the Director General and Senior Manager of the Africa Office of Iran Trade Promotion Organization, with the aim of expanding exports of Golrang’s pharmaceutical products to the African continent.
According to the Public Relations Department of Golrang Pharmaceutical Group, at the beginning of the meeting—which was attended by Mr. Narimani, Vice President, and Mr. Keykha, Export Advisor of Golrang Pharmaceutical Investment Group, as well as Mr. Shahrouzi, CEO of Arian Salamat Sina Company—Mr. Bameh, Head of Public Relations and Branding of the Investment Group, outlined the export capabilities and achievements of the 14 subsidiary companies of the Golrang Pharmaceutical Holding.
During the meeting, Mr. Safari, Director General of the Africa Office, referred to plans for expanding economic cooperation with African countries and emphasized the importance of increasing Iran’s presence in the markets of this continent.
Noting that Africa, with 55 countries and a population of over 1.4 billion, offers numerous opportunities for joint cooperation—particularly in the field of knowledge-based products—Mr. Safari stated that Golrang Group, as one of the pioneers in pharmaceutical production and a key player in the export development program, can play a central role in implementing the strategy of “focusing on joint production” in Africa. He added: “Our new approach in this office is to move toward knowledge-based cooperation and to leverage shared technical expertise to penetrate African markets.”
In closing, emphasizing the need to focus on joint production and the use of knowledge-based capacities, he invited Golrang Group to nominate a representative to join the First Vice President’s upcoming delegation to Niger, Mauritania, and Senegal, and announced plans to dispatch specialized knowledge-based delegations to target countries such as Tunisia.
The goal of Golrang Pharmaceutical Investment Group is to expand exports of its high-quality pharmaceutical products to diverse markets, including those within the African continent. Relying on the scientific, technological, and production capacities of its subsidiary companies, and in line with Iran’s macro policies for the development of non-oil exports, the Group seeks to establish sustainable infrastructure for long-term presence in target markets and to expand regional cooperation in the fields of pharmaceuticals and healthcare.
